Skip to main content

Therma Bright Inc(THRM-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.055
Day High0.055
Open:0.055
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Therma Bright Announces Follow-On Order from Horizon Health as Venowave(TM) Gains Traction in U.S. Vascular Markets
Therma Bright Signs New Strategic Customer, Horizon Health, Currently Selling over 35,000 Compression Products Annually
Therma Bright Portfolio Update: Inretio Successfully Completes First-in-Human Cohort for PREVA(TM) Stroke Platform; Targets 2026 U.S. FDA Trial
Therma Bright Sells an Additional 200-Units of Venowave(TM) to Strategic Distribution Partner Gen-X Med
Therma Bright Inc. Investee Company, InStatin Expands its Inhaled Statin Programs to include COPD (Chronic Obstructive Pulmonary Disease) as its Lead Indication.
Therma Bright Appoints US Healthcare Veteran Michael Raimondo to the Board of Directors
Therma Bright Expands Relationship with Distribution Partner Gen-X Med for Venowave(TM) Sales
Therma Bright Proposes to Amend Certain Warrants
Therma Bright Announces Share Consolidation
Therma Bright Inc. Announces Share Consolidation
Therma Bright Proposes to Amend Certain Warrants and Negotiates Debt Settlements
Therma Bright Inc. Provides Update on InStatin Development, Announcement of Key Strategic Advisor and Highlights Preclinical and IP Progress at InStatin
Therma Bright Secures New Customer Initial Purchase Order, Signaling Market Confidence

Profile

Therma Bright Inc is a developer and partner in a range of proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with solutions to address important medical and healthcare challenges. The Company is developing, acquiring, manufacturing and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace focused on 3 key strategic areas: respiratory disease, vascular health, and consumer medical devices.